All Stories

  1. Non-dipping and higher nocturnal blood pressure are associated with risk of mortality and development of kidney disease in type 1 diabetes

    Article • Journal of Diabetes and its Complications, September 2022, Elsevier

    Dr Frederik Persson

  2. Dapagliflozin Improves the Urinary Proteomic Kidney-Risk Classifier CKD273 in Type 2 Diabetes with Albuminuria – a Randomized Clinical Trial

    Article • Diabetes Care, August 2022, American Diabetes Association

    Dr Frederik Persson

  3. Sodium–glucose cotransporter 2 inhibitors as adjunct therapy for type 1 diabetes and the benefit on cardiovascular and renal disease evaluated by Steno risk engines

    Article • Journal of Diabetes and its Complications, August 2022, Elsevier

    Dr Frederik Persson

  4. Is Time-Restricted Eating Safe in the Treatment of Type 2 Diabetes?—A Review of Intervention Studies

    Article • Nutrients, May 2022, MDPI AG

    Dr Frederik Persson

  5. Flexible inclusion of dialogue about psychosocial aspects of life with type 1 diabetes in routine consultations: A study of a questionnaire‐based dialogue tool to promote person‐centred support

    Article • Diabetic Medicine, May 2022, Wiley

    Dr Frederik Persson

  6. Acute and Long-Term Treatment With Dapagliflozin and Association With Serum Soluble Urokinase Plasminogen Activator Receptor

    Article • Frontiers in Pharmacology, April 2022, Frontiers

    Dr Frederik Persson

  7. Impact of random variation in albuminuria and estimated glomerular filtration rate on patient enrolment and duration of clinical trials in nephrology

    Article • Diabetes Obesity and Metabolism, February 2022, Wiley

    Dr Frederik Persson

  8. The importance of addressing multiple risk markers in type 2 diabetes: Results from the LEADER and SUSTAIN 6 trials

    Article • Diabetes Obesity and Metabolism, November 2021, Wiley

    Dr Frederik Persson

  9. Endothelial glycocalyx and cardio-renal risk factors in type 1 diabetes

    Article • PLoS ONE, July 2021, PLOS

    Dr Frederik Persson

  10. A large remaining potential in lipid‐lowering drug treatment in the type 2 diabetes population: A Danish nationwide cohort study

    Article • Diabetes Obesity and Metabolism, July 2021, Wiley

    Dr Frederik Persson

  11. Faecal biomarkers in type 1 diabetes with and without diabetic nephropathy

    Article • Scientific Reports, July 2021, Springer Science + Business Media

    Dr Frederik Persson

  12. Improving frequency of urinary albumin testing in type 2 diabetes in primary care — An analysis of cross-sectional studies in Denmark

    Article • Primary Care Diabetes, July 2021, Elsevier

    Dr Frederik Persson

  13. What Have We Learned so Far From the Use of Sodium-Glucose Cotransporter 2 Inhibitors in Clinical Practice?

    Article • Advances in Chronic Kidney Disease, July 2021, Elsevier

    Dr Frederik Persson

  14. Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial

    Article • Diabetes Care, June 2021, American Diabetes Association

    Dr Frederik Persson

  15. A Validated Prediction Model for End-Stage Kidney Disease in Type 1 Diabetes. Diabetes Care 2021;44:901–907

    Article • Diabetes Care, May 2021, American Diabetes Association

    Dr Frederik Persson

  16. The effect of liraglutide and sitagliptin on oxidative stress in persons with type 2 diabetes

    Article • Scientific Reports, May 2021, Springer Science + Business Media

    Dr Frederik Persson

  17. Risk factor management of type 2 diabetic patients in primary care in the Scandinavian countries between 2003 and 2015

    Article • Primary Care Diabetes, April 2021, Elsevier

    Dr Frederik Persson

  18. Importance of standardizing renal outcomes in clinical trials: illustration by recent sodium glucose cotransporter 2 inhibitor studies

    Article • Kidney International, March 2021, Elsevier

    Dr Frederik Persson

  19. A Validated Prediction Model for End-Stage Kidney Disease in Type 1 Diabetes

    Article • Diabetes Care, January 2021, American Diabetes Association

    Dr Frederik Persson

  20. Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Post Hoc Analysis of the LEADER Trial

    Article • Diabetes Care, January 2021, American Diabetes Association

    Dr Frederik Persson

  21. Copeptin and renal function decline, cardiovascular events and mortality in type 1 diabetes

    Article • Nephrology Dialysis Transplantation, December 2020, Oxford University Press (OUP)

    Dr Frederik Persson

  22. Assessment of the sublingual microcirculation with the GlycoCheck system: Reproducibility and examination conditions

    Article • PLoS ONE, December 2020, PLOS

    Dr Frederik Persson

  23. Linking Kidney and Cardiovascular Complications in Diabetes—Impact on Prognostication and Treatment: The 2019 Edwin ...

    Article • Diabetes, December 2020, American Diabetes Association

    Peter rossing, Dr Frederik Persson

  24. Visit‐to‐visit variability of clinical risk markers in relation to long‐term complications in type 1 diabetes

    Article • Diabetic Medicine, November 2020, Wiley

    Dr Frederik Persson

  25. No effects of dapagliflozin, metformin or exercise on plasma glucagon concentrations in individuals with prediabetes: A post hoc analysis from the randomized controlled PRE‐D trial

    Article • Diabetes Obesity and Metabolism, November 2020, Wiley

    Dr Frederik Persson

  26. The Glycemic Effect of Liraglutide Evaluated by Continuous Glucose Monitoring in Persons with Type 2 Diabetes Receiving Dialysis

    Article • October 2020, Karger Publishers

    Dr Frederik Persson

  27. Irbesartan treatment does not influence plasma levels of the dicarbonyls methylglyoxal, glyoxal and 3‐deoxyglucosone in participants with type 2 diabetes and microalbuminuria: An IRMA2 sub‐study

    Article • Diabetic Medicine, October 2020, Wiley

    Dr Frederik Persson

  28. The effects of dapagliflozin, metformin or exercise on glycaemic variability in overweight or obese individuals with prediabetes (the PRE-D Trial): a multi-arm, randomised, controlled trial

    Article • Diabetologia, October 2020, Springer Science + Business Media

    Dr Frederik Persson

  29. Achieving a useful and person‐centred diabetes consultation is a shared responsibility between diabetologists and people with diabetes: a qualitative study of perspectives from people with type 1 diabetes

    Article • Diabetic Medicine, September 2020, Wiley

    Dr Frederik Persson

  30. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics

    Article • Nephrology Dialysis Transplantation, August 2020, Oxford University Press (OUP)

    Bergur Stefansson, Dr Frederik Persson

  31. Cardiovascular and renal outcomes by baseline albuminuria status and renal function: Results from the LEADER randomized trial

    Article • Diabetes Obesity and Metabolism, August 2020, Wiley

    Dr Frederik Persson

  32. Oral treatment of glucocorticoid‐induced diabetes mellitus: A systematic review

    Article • International Journal of Clinical Practice, July 2020, Hindawi Publishing Corporation

    Dr Frederik Persson

  33. Effect of dapagliflozin on cardiac function in people with type 2 diabetes and albuminuria – A double blind randomized placebo-controlled crossover trial

    Article • Journal of Diabetes and its Complications, July 2020, Elsevier

    Dr Frederik Persson

  34. Lipoprotein(a)and renal function decline, cardiovascular disease and mortality in type 2 diabetes and microalbuminuria

    Article • Journal of Diabetes and its Complications, July 2020, Elsevier

    Dr Frederik Persson

  35. Drug‐drug interaction between warfarin and statins: A Danish cohort study

    Article • British Journal of Clinical Pharmacology, June 2020, Wiley

    Dr Frederik Persson

  36. Study rationale and design of the EANITIATE study (EmpAgliflozin compared to NPH Insulin for sTeroId diAbeTEs) - a randomized, controlled, multicenter trial of safety and efficacy of treatment with empagliflozin compared with NPH-insulin in patients wi...

    Article • BMC Endocrine Disorders, June 2020, Springer Science + Business Media

    Dr Frederik Persson

  37. Guía ESC 2019 sobre diabetes, prediabetes y enfermedad cardiovascular, en colaboración con la European Association for the Study of Diabetes (EASD)

    Article • Revista Española de Cardiología, May 2020, Elsevier

    Prof HECTOR BUENO, Dr Frederik Persson

  38. Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial

    Article • The Lancet Diabetes & Endocrinology, April 2020, Elsevier

    Dr Frederik Persson

  39. Comments on the 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases

    Article • European Heart Journal, December 2019, Oxford University Press (OUP)

    Dr Frederik Persson

  40. Inflammation Leads the Way on the ROADMAP to Diabetic Kidney Disease

    Article • Kidney International Reports, October 2019, Elsevier

    Dr Frederik Persson

  41. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD

    Article • European Heart Journal, August 2019, Oxford University Press (OUP)

    Prof HECTOR BUENO, Dr Frederik Persson

  42. The Impact of Sotagliflozin on Renal Function, Albuminuria, Blood Pressure, and Hematocrit in Adults With Type 1 Diabetes

    Article • Diabetes Care, August 2019, American Diabetes Association

    Dr Frederik Persson

  43. Progressive Decline in Estimated Glomerular Filtration Rate in Patients With Diabetes After Moderate Loss in Kidney Function—Even Without Albuminuria

    Article • Diabetes Care, June 2019, American Diabetes Association

    Dr Frederik Persson

  44. Improvements in albuminuria and chronic kidney disease progression with the appetite suppressant lorcaserin

    Article • Kidney International, June 2019, Elsevier

    Dr Frederik Persson

  45. 895-P: Effects of Dapagliflozin, Metformin, or Exercise on Markers of Cardiometabolic Risk: The PRE-D Trial

    Article • Diabetes, June 2019, American Diabetes Association

    Dr Frederik Persson

  46. 1467-P: National Trends in the Use of Lipid-Lowering Drugs among Type 2 Diabetes Patients in Denmark from 1997 to 2017

    Article • Diabetes, June 2019, American Diabetes Association

    Dr Frederik Persson

  47. 905-P: Safety, Adherence, and Treatment Satisfaction with Dapagliflozin, Metformin, or Exercise in Individuals with Prediabetes: The Pre-D Trial

    Article • Diabetes, June 2019, American Diabetes Association

    Dr Frederik Persson

  48. 901-P: Effects of Dapagliflozin, Metformin, or Exercise on Glycaemic Variability and Mean Glucose Levels in Prediabetes: The PRE-D Trial

    Article • Diabetes, June 2019, American Diabetes Association

    Dr Frederik Persson

  49. 526-P: Dapagliflozin Improves the Urinary CKD273 Proteomic Score When Added to Renin-Angiotensin Blockade in Patients with Type 2 Diabetes and Nephropathy

    Article • Diabetes, June 2019, American Diabetes Association

    Dr Frederik Persson

  50. 1196-P: The Impact of Sotagliflozin on Renal Function, Albuminuria, and Blood Pressure in Adults with Type 1 Diabetes (T1D)

    Article • Diabetes, June 2019, American Diabetes Association

    Dr Frederik Persson

  51. Effects of Dapagliflozin on Volume Status When Added to Renin–Angiotensin System Inhibitors

    Article • Journal of Clinical Medicine, May 2019, MDPI AG

    Dr Frederik Persson

  52. Soluble Urokinase Plasminogen Activator Receptor Predicts Cardiovascular Events, Kidney Function Decline, and Mortality in Patients With Type 1 Diabetes

    Article • Diabetes Care, March 2019, American Diabetes Association

    Dr Frederik Persson

  53. Increasing ESKD in Diabetes in the Land Down Under: What Can Be Done, We Must Wonder

    Article • American Journal of Kidney Diseases, March 2019, Elsevier

    Dr Frederik Persson

  54. Clinical care and other categories posters: Structure/systems of care and healthcare delivery

    Article • Diabetic Medicine, March 2019, Wiley

    Dr Frederik Persson

  55. Pleiotropic effects of liraglutide in patients with type 2 diabetes and moderate renal impairment: Individual effects of treatment

    Article • Diabetes Obesity and Metabolism, February 2019, Wiley

    Dr Frederik Persson

  56. Urinary Proteomics and Precision Medicine for Chronic Kidney Disease: Current Status and Future Perspectives

    Article • PROTEOMICS - CLINICAL APPLICATIONS, January 2019, Wiley

    Dr Frederik Persson

  57. Application of urinary proteomics as possible risk predictor of renal and cardiovascular complications in patients with type 2-diabetes and microalbuminuria

    Article • Journal of Diabetes and its Complications, December 2018, Elsevier

    Dr Frederik Persson

  58. Different patterns of second-line treatment in type 2 diabetes after metformin monotherapy in Denmark, Finland, Norway and Sweden (D360 Nordic): A multinational observational study

    Article • Endocrinology Diabetes & Metabolism, August 2018, Wiley

    Johan Bodegard, Dr Frederik Persson

  59. Interpretation of HbA1cin primary care and potential influence of anaemia and chronic kidney disease: an analysis from the Copenhagen Primary Care Laboratory (CopLab) Database

    Article • Diabetic Medicine, August 2018, Wiley

    Dr Frederik Persson

  60. Urinary tubular biomarkers as predictors of kidney function decline, cardiovascular events and mortality in microalbuminuric type 2 diabetic patients

    Article • Acta Diabetologica, August 2018, Springer Science + Business Media

    Dr Frederik Persson

  61. NT-proBNP predicts the cardio-renal response to aliskiren in patients with type 2 diabetes at high renal and cardiovascular risk

    Article • Diabetes Obesity and Metabolism, July 2018, Wiley

    Professor john j mcmurray, Dr Frederik Persson

  62. Characteristics of high- and low-risk individuals in the PRIORITY study: urinary proteomics and mineralocorticoid receptor antagonism for prevention of diabetic nephropathy in Type 2 diabetes

    Article • Diabetic Medicine, June 2018, Wiley

    Nete Tofte, Dr Frederik Persson

  63. Aldosterone Blockade Added to Renin-Angiotensin System Blockade to Reduce Albuminuria—A Path for Improved Renoprotection?

    Article • The American Journal of the Medical Sciences, May 2018, Elsevier

    Dr Frederik Persson

  64. Serum uric acid and progression of diabetic nephropathy in type 1 diabetes

    Article • Journal of Diabetes and its Complications, May 2018, Elsevier

    Dr Frederik Persson

  65. SP418COLLAGEN TYPE III DEGRADATION IS ASSOCIATED WITH DETERIORATION OF KIDNEY FUNCTION IN PATIENTS WITH TYPE 2 DIABETES WITH MICROALBUMINURIA.

    Article • Nephrology Dialysis Transplantation, May 2018, Oxford University Press (OUP)

    Dr Frederik Persson

  66. Growth differentiation factor-15 and fibroblast growth factor-23 are associated with mortality in type 2 diabetes – An observational follow-up study

    Article • PLoS ONE, April 2018, PLOS

    Dr Frederik Persson

  67. Uric acid is not associated with diabetic nephropathy and other complications in type 1 diabetes

    Article • Nephrology Dialysis Transplantation, April 2018, Oxford University Press (OUP)

    Dr Frederik Persson

  68. Prognosis and treatment of diabetic nephropathy: Recent advances and perspectives

    Article • Néphrologie & Thérapeutique, April 2018, Elsevier

    Dr Frederik Persson

  69. The effect of uric acid lowering treatment on albuminuria and renal function in Type 1 diabetes: a randomized clinical trial

    Article • Diabetic Medicine, February 2018, Wiley

    Dr Frederik Persson

  70. YKL-40 in dialysis patients: another candidate in the quest for useful biomarkers in nephrology

    Article • Kidney International, January 2018, Elsevier

    Dr Frederik Persson

  71. Diagnosis of diabetic kidney disease: state of the art and future perspective

    Article • Kidney International Supplements, January 2018, Elsevier

    Dr Frederik Persson

  72. Empagliflozin reduces albuminuria—a promise for better cardiorenal protection from the EMPA-REG OUTCOME trial

    Article • Annals of Translational Medicine, December 2017, AME Publishing Company

    Dr Frederik Persson

  73. Plasma high-sensitivity troponin T predicts end-stage renal disease and cardiovascular and all-cause mortality in patients with type 1 diabetes and diabetic nephropathy

    Article • Kidney International, November 2017, Elsevier

    Dr Frederik Persson

  74. Pooled Analysis of Multiple Crossover Trials To Optimize Individual Therapy Response to Renin-Angiotensin-Aldosterone System Intervention

    Article • Clinical Journal of the American Society of Nephrology, October 2017, American Society of Nephrology

    Dr Frederik Persson

  75. Urinary albumin and 8-oxo-7,8-dihydroguanosine as markers of mortality and cardiovascular disease during 19 years after diagnosis of type 2 diabetes – A comparative study of two markers to identify high risk patients

    Article • Redox Biology, October 2017, Elsevier

    Dr. Rasmus Køster-Rasmussen, Dr Frederik Persson

  76. Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational study

    Article • Diabetes Obesity and Metabolism, September 2017, Wiley

    Johan Bodegard, Dr Frederik Persson

  77. Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis

    Article • The Lancet Diabetes & Endocrinology, September 2017, Elsevier

    Dr Frederik Persson

  78. Symmetric and asymmetric dimethylarginine as risk markers of cardiovascular disease, all-cause mortality and deterioration in kidney function in persons with type 2 diabetes and microalbuminuria

    Article • Cardiovascular Diabetology, July 2017, Springer Science + Business Media

    Dr Frederik Persson

  79. Toe–brachial index as a predictor of cardiovascular disease and all-cause mortality in people with type 2 diabetes and microalbuminuria

    Article • Diabetologia, July 2017, Springer Science + Business Media

    Dr Frederik Persson

  80. Effect of weight reductions on estimated kidney function: Post-hoc analysis of two randomized trials

    Article • Journal of Diabetes and its Complications, July 2017, Elsevier

    Dr Frederik Persson

  81. Protocol for a randomised controlled trial of the effect of dapagliflozin, metformin and exercise on glycaemic variability, body composition and cardiovascular risk in prediabetes (the PRE-D Trial)

    Article • BMJ Open, May 2017, BMJ

    Dr Frederik Persson

  82. Intensified multifactorial intervention in type 2 diabetics with microalbuminuria leads to long-term renal benefits

    Article • Kidney International, April 2017, Elsevier

    Dr Frederik Persson

  83. Differential Effects of Dapagliflozin on Cardiovascular Risk Factors at Varying Degrees of Renal Function

    Article • Clinical Journal of the American Society of Nephrology, March 2017, American Society of Nephrology

    Dr Frederik Persson

  84. Incidence of Ketoacidosis in the Danish Type 2 Diabetes Population Before and After Introduction of Sodium–Glucose Cotransporter 2 Inhibitors—A Nationwide, Retrospective Cohort Study, 1995–2014

    Article • Diabetes Care, March 2017, American Diabetes Association

    Dr Frederik Persson

  85. Effects of liraglutide on cardiovascular risk biomarkers in patients with type 2 diabetes and albuminuria: A sub-analysis of a randomized, placebo-controlled, double-blind, crossover trial

    Article • Diabetes Obesity and Metabolism, March 2017, Wiley

    Dr Frederik Persson

  86. Effect of large weight reductions on measured and estimated kidney function

    Article • BMC Nephrology, February 2017, Springer Science + Business Media

    Dr Frederik Persson

  87. Variability in response to albuminuria-lowering drugs: true or random?

    Article • British Journal of Clinical Pharmacology, February 2017, Wiley

    Dr Frederik Persson

  88. Predicting albuminuria response to spironolactone treatment with urinary proteomics in patients with type 2 diabetes and hypertension

    Article • Nephrology Dialysis Transplantation, January 2017, Oxford University Press (OUP)

    Dr Frederik Persson

  89. Higher Parathyroid Hormone Level Is Associated With Increased Arterial Stiffness in Type 1 Diabetes

    Article • Diabetes Care, January 2017, American Diabetes Association

    Dr Frederik Persson

  90. Pleiotropic effects of liraglutide treatment on renal risk factors in type 2 diabetes: Individual effects of treatment

    Article • Journal of Diabetes and its Complications, January 2017, Elsevier

    Dr Frederik Persson

  91. The effect of liraglutide on renal function: A randomized clinical trial

    Article • Diabetes Obesity and Metabolism, November 2016, Wiley

    Dr Frederik Persson

  92. Renin angiotensin system blockade reduces urinary levels of soluble urokinase plasminogen activator receptor (suPAR) in patients with type 2 diabetes

    Article • Journal of Diabetes and its Complications, November 2016, Elsevier

    Dr Frederik Persson

  93. Noninvasive diagnosis of chronic kidney diseases using urinary proteome analysis

    Article • Nephrology Dialysis Transplantation, October 2016, Oxford University Press (OUP)

    Dr Frederik Persson

  94. Urinary proteomics predict onset of microalbuminuria in normoalbuminuric type 2 diabetic patients, a sub-study of the DIRECT-Protect 2 study

    Article • Nephrology Dialysis Transplantation, August 2016, Oxford University Press (OUP)

    Dr Frederik Persson

  95. Prevention of microalbuminuria using early intervention with renin-angiotensin system inhibitors in patients with type 2 diabetes: A systematic review

    Article • Journal of the Renin-Angiotensin-Aldosterone System, August 2016, SAGE Publications

    Dr Frederik Persson

  96. Multifactorial intervention to prevent cardiovascular disease in patients with early rheumatoid arthritis: protocol for a multicentre randomised controlled trial

    Article • BMJ Open, April 2016, BMJ

    Dr Frederik Persson

  97. Renal outcomes with aliskiren in patients with type 2 diabetes: a prespecified secondary analysis of the ALTITUDE randomised controlled trial

    Article • The Lancet Diabetes & Endocrinology, April 2016, Elsevier

    Professor john j mcmurray, Dr Frederik Persson

  98. Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy in TYpe 2 diabetic patients with normoalbuminuria (PRIORITY): essential study design and rationale of a randomised clinical multicentre trial

    Article • BMJ Open, March 2016, BMJ

    Dr Frederik Persson, prof alberto ortiz

  99. Is a reduction in albuminuria associated with renal and cardiovascular protection? Apost hocanalysis of the ALTITUDE trial

    Article • Diabetes Obesity and Metabolism, January 2016, Wiley

    Professor john j mcmurray, Dr Frederik Persson

  100. The influence of pharmaceutically induced weight changes on estimates of renal function: A patient-level pooled analysis of seven randomised controlled trials of glucose lowering medication

    Article • Journal of Diabetes and its Complications, November 2015, Elsevier

    Dr Frederik Persson

  101. Nordic Longitudinal Data from Electronic Medical Records and Full Population National Registers: Unique Opportunities for New Insights in Benefit of Diabetes Patients

    Article • Value in Health, November 2015, Elsevier

    Dr Frederik Persson

  102. Glucagon-like peptide 1 receptor agonist (GLP-1 RA): long-term effect on kidney function in patients with type 2 diabetes

    Article • Journal of Diabetes and its Complications, July 2015, Elsevier

    Dr Frederik Persson

  103. Improving the effectiveness of short-term courses for multidisciplinary health care professionals

    Article • Practical Diabetes, June 2015, Wiley

    Dr Frederik Persson

  104. Effects of RAS inhibitors on diabetic retinopathy

    Article • The Lancet Diabetes & Endocrinology, May 2015, Elsevier

    Dr Frederik Persson

  105. Diagnosis and Prediction of CKD Progression by Assessment of Urinary Peptides

    Article • Journal of the American Society of Nephrology, January 2015, American Society of Nephrology

    Dr Frederik Persson, prof alberto ortiz

  106. Number and Frequency of Albuminuria Measurements in Clinical Trials in Diabetic Nephropathy

    Article • Clinical Journal of the American Society of Nephrology, January 2015, American Society of Nephrology

    Dr Frederik Persson

  107. Microalbuminuria: A parameter that has changed diabetes care

    Article • Diabetes Research and Clinical Practice, January 2015, Elsevier

    Dr Frederik Persson

  108. Time course and mechanisms of the anti-hypertensive and renal effects of liraglutide treatment

    Article • Diabetic Medicine, October 2014, Wiley

    Dr Frederik Persson

  109. Multicentre prospective validation of a urinary peptidome-based classifier for the diagnosis of type 2 diabetic nephropathy

    Article • Nephrology Dialysis Transplantation, March 2014, Oxford University Press (OUP)

    Dr Frederik Persson, prof alberto ortiz

  110. Sequential RAAS Blockade: Is It Worth the Risk?

    Article • Advances in Chronic Kidney Disease, March 2014, Elsevier

    Dr Frederik Persson

  111. Tissue Renin–Angiotensin Systems: A Unifying Hypothesis of Metabolic Disease

    Article • Frontiers in Endocrinology, January 2014, Frontiers

    Dr Frederik Persson

  112. Improving peptide relative quantification in MALDI-TOF MS for biomarker assessment

    Article • PROTEOMICS, October 2013, Wiley

    Dr Frederik Persson

  113. Direct renin inhibition in chronic kidney disease

    Article • British Journal of Clinical Pharmacology, September 2013, Wiley

    Dr Frederik Persson

  114. Urinary renin and angiotensinogen in type 2 diabetes

    Article • Journal of Hypertension, August 2013, Wolters Kluwer Health

    Dr Frederik Persson

  115. A prediction of the renal and cardiovascular efficacy of aliskiren in ALTITUDE using short-term changes in multiple risk markers

    Article • European Journal of Preventive Cardiology, March 2013, SAGE Publications

    Dr Frederik Persson

  116. 24-hour central aortic systolic pressure and 24-hour central pulse pressure are related to diabetic complications in type 1 diabetes – a cross-sectional study

    Article • Cardiovascular Diabetology, January 2013, Springer Science + Business Media

    Dr Frederik Persson

  117. Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes

    Article • New England Journal of Medicine, December 2012, New England Journal of Medicine (NEJM/MMS)

    Dr Frederik Persson, Professor john j mcmurray, Massimo Volpe

  118. Arterial Stiffness Is Associated With Cardiovascular, Renal, Retinal, and Autonomic Disease in Type 1 Diabetes

    Article • Diabetes Care, November 2012, American Diabetes Association

    Dr Frederik Persson

  119. Levels of NT-proBNP, markers of low-grade inflammation, and endothelial dysfunction during spironolactone treatment in patients with diabetic kidney disease

    Article • Journal of the Renin-Angiotensin-Aldosterone System, October 2012, SAGE Publications

    Dr Frederik Persson

  120. A urinary peptide biomarker set predicts worsening of albuminuria in type 2 diabetes mellitus

    Article • Diabetologia, October 2012, Springer Science + Business Media

    Dr Frederik Persson

  121. Urinary Proteomics for Early Diagnosis in Diabetic Nephropathy

    Article • Diabetes, August 2012, American Diabetes Association

    Dr Frederik Persson

  122. Discrepancy Between Tonometric Ambulatory and Cuff-Based Office Blood Pressure Measurements in Patients With Type 1 Diabetes

    Article • Journal of Clinical Hypertension, August 2012, Wiley

    Dr Frederik Persson

  123. Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study

    Article • Diabetic Medicine, July 2012, Wiley

    Dr Frederik Persson

  124. Ambulatory Tonometric Blood Pressure Measurements in Patients with Diabetes

    Article • Diabetes Technology & Therapeutics, June 2012, Mary Ann Liebert Inc

    Dr Frederik Persson

  125. Implementation of proteomic biomarkers: making it work

    Article • European Journal of Clinical Investigation, April 2012, Wiley

    Dr Frederik Persson, prof alberto ortiz

  126. High YKL-40 levels predict mortality in patients with type 2 diabetes

    Article • Diabetes Research and Clinical Practice, April 2012, Elsevier

    Dr Frederik Persson

  127. Impact of glycaemic control on the effect of direct renin inhibition in the AVOID study

    Article • Journal of the Renin-Angiotensin-Aldosterone System, February 2012, SAGE Publications

    Dr Frederik Persson

  128. Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE)

    Article • Journal of the Renin-Angiotensin-Aldosterone System, February 2012, SAGE Publications

    Dr Frederik Persson, Professor john j mcmurray

  129. Impact of aliskiren treatment on urinary aldosterone levels in patients with type 2 diabetes and nephropathy: an AVOID substudy

    Article • Journal of the Renin-Angiotensin-Aldosterone System, August 2011, SAGE Publications

    Dr Frederik Persson

  130. Initial Angiotensin Receptor Blockade-Induced Decrease in Albuminuria Is Associated With Long-Term Renal Outcome in Type 2 Diabetic Patients With Microalbuminuria: A post hoc analysis of the IRMA-2 trial

    Article • Diabetes Care, July 2011, American Diabetes Association

    Dr Frederik Persson

  131. Long-Term Effects of Irbesartan Treatment and Smoking on Nucleic Acid Oxidation in Patients With Type 2 Diabetes and Microalbuminuria: An Irbesartan in Patients With Type 2 Diabetes and Microalbuminuria (IRMA 2) substudy

    Article • Diabetes Care, March 2011, American Diabetes Association

    Dr Frederik Persson

  132. Irbesartan treatment does not influence plasma levels of the advanced glycation end products N (1-carboxymethyl)lysine and N (1-carboxyethyl)lysine in patients with type 2 diabetes and microalbuminuria. A randomized controlled trial

    Article • Nephrology Dialysis Transplantation, March 2011, Oxford University Press (OUP)

    Dr Frederik Persson, Professor Isabel Ferreira

  133. Elevated NT-proBNP and coronary calcium score in relation to coronary artery disease in asymptomatic type 2 diabetic patients with elevated urinary albumin excretion rate

    Article • Nephrology Dialysis Transplantation, March 2011, Oxford University Press (OUP)

    Dr Frederik Persson

  134. Aliskiren in Combination with Losartan Reduces Albuminuria Independent of Baseline Blood Pressure in Patients with Type 2 Diabetes and Nephropathy

    Article • Clinical Journal of the American Society of Nephrology, February 2011, American Society of Nephrology

    Dr Frederik Persson

  135. Impact of Baseline Renal Function on the Efficacy and Safety of Aliskiren Added to Losartan in Patients With Type 2 Diabetes and Nephropathy

    Article • Diabetes Care, August 2010, American Diabetes Association

    Dr Frederik Persson

  136. Optimal antiproteinuric dose of aliskiren in type 2 diabetes mellitus: a randomised crossover trial

    Article • Diabetologia, May 2010, Springer Science + Business Media

    Dr Frederik Persson

  137. Renal Effects of Aliskiren Compared With and in Combination With Irbesartan in Patients With Type 2 Diabetes, Hypertension, and Albuminuria

    Article • Diabetes Care, July 2009, American Diabetes Association

    Dr Frederik Persson

  138. Optimal dose of lisinopril for renoprotection in type 1 diabetic patients with diabetic nephropathy: a randomised crossover trial

    Article • Diabetologia, October 2008, Springer Science + Business Media

    Dr Frederik Persson

  139. YKL-40, a Marker of Inflammation and Endothelial Dysfunction, Is Elevated in Patients With Type 1 Diabetes and Increases With Levels of Albuminuria

    Article • Diabetes Care, October 2008, American Diabetes Association

    Dr Frederik Persson

  140. Aliskiren Combined with Losartan in Type 2 Diabetes and Nephropathy

    Article • New England Journal of Medicine, June 2008, New England Journal of Medicine (NEJM/MMS)

    Dr Frederik Persson, DAVIDE CARVALHO

  141. Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes

    Article • Kidney International, June 2008, Elsevier

    Dr Frederik Persson

  142. Endothelial dysfunction and inflammation predict development of diabetic nephropathy in the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria (IRMA 2) study

    Article • Scandinavian Journal of Clinical and Laboratory Investigation, January 2008, Taylor & Francis

    Dr Frederik Persson

  143. Irbesartan Treatment Reduces Biomarkers of Inflammatory Activity in Patients With Type 2 Diabetes and Microalbuminuria: An IRMA 2 Substudy

    Article • Diabetes, November 2006, American Diabetes Association

    Dr Frederik Persson

  144. Development and validation of a brief, descriptive Danish pain questionnaire (BDDPQ)

    Article • Acta Anaesthesiologica Scandinavica, April 2004, Wiley

    Dr Frederik Persson

  145. Postural Stability after Inguinal Herniorrhaphy under Local Infiltration Anaesthesia

    Article • The European Journal of Surgery, June 2001, Oxford University Press (OUP)

    Dr Frederik Persson